177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
Metrics: PDF 542 views | HTML 1426 views | ?
Finn E. von Eyben1, Timo Kiljunen2, Timo Joensuu2, Kalevi Kairemo2, Christian Uprimny3 and Irene Virgolini3
1Center of Tobacco Control Research, Odense, Denmark
2Docrates Cancer Center, Helsinki, Finland
3Department of Nuclear Medicine, Innsbruck University Hospital, Innsbruck, Austria
Finn E. von Eyben, email: email@example.com
Keywords: abiraterone, cross-over study, external beam radiotherapy, lutetium radiolabled prostate membrane specific antigen radioligand therapy, metastatic prostate cancer
Received: May 12, 2017 Accepted: July 11, 2017 Published: August 02, 2017
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. 177Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report describes a patient with a third recurrence in lymph nodes. The recurrence was treated with 177Lu-PSMA radioligand therapy instead of chemotherapy with docetaxel. The effect was in part evaluated relative to that of two established salvage treatments. Prior salvage radiotherapy and abiraterone of the first and second recurrence in lymph nodes had given only a partial reduction of PSA. Nevertheless within five months of follow-up, 177Lu-PSMA radioligand therapy of the third recurrence in lymph nodes reduced PSA for a period to unmeasurable levels. 177Lu-PSMA radioligand therapy gave only mild adverse effects. In conclusion, for a patient with lymph node metastatic prostate cancer, 177Lu-PSMA-617 radioligand therapy had an attractive therapeutic profile. A follow-up study of similar patients is being planned.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.